The Ozempic Shortage Is Over. So Why Can't You Afford It?

On February 21, 2025, the FDA formally removed injectable semaglutide from its drug shortage list. After more than a year of limited supply that left patients scrambling, Novo Nordisk confirmed it could meet demand for all dose strengths of both Ozempic and Wegovy.

The supply problem was solved. The price problem was not.

What the Shortage Changed

During the shortage, something interesting happened: patients who couldn't get branded semaglutide discovered compounded alternatives. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, pharmacies can compound copies of commercially available drugs when those drugs are on the FDA shortage list.

Compounded semaglutide emerged as a lower-cost option for patients who either couldn't access branded Wegovy or couldn't afford it. Telehealth platforms built entire businesses around this access gap.

Then the shortage ended, and the legal ground shifted.

The Post-Shortage Legal Battle

With semaglutide off the shortage list, the 503A exemption for compounding "essentially a copy" narrowed significantly. The FDA's position: pharmacies should stop compounding semaglutide unless their specific formulation is demonstrably different from the branded product.

The response was immediate. Compounding pharmacies and telehealth companies filed legal challenges. Some argued their formulations were not "essentially a copy" because they used different doses, concentrations, or inactive ingredients. Others challenged the FDA's authority to broadly restrict compounding.

The SAFE Drugs Act of 2025, introduced in Congress in December 2025, proposed to codify the "essentially a copy" definition and cap compounding volume. As of April 2026, the bill hasn't passed, and courts are still adjudicating the underlying disputes.

Meanwhile, patients are caught in the middle.

The Pricing Reality

Branded semaglutide costs between $1,000 and $1,500 per month at list price, depending on the formulation and dose. Insurance coverage varies widely. Many plans require prior authorization and step therapy before covering GLP-1 medications for weight management. Medicare Part D began covering obesity medications in 2026, but with significant cost-sharing.

The U.S. remains one of the only developed nations without government drug price negotiation for most medications. The Inflation Reduction Act of 2022 introduced limited Medicare negotiation, but semaglutide was not among the first drugs selected.

The result: a medication with strong clinical evidence for obesity treatment remains inaccessible to millions of patients purely because of cost.

The Compounding Trade-Off

Compounded semaglutide (available by consultation) offers a lower-cost alternative, but it comes with real trade-offs that patients should understand:

What you gain: Lower cost, potentially broader access outside the insurance system.

What you give up: FDA approval, which means the compounded product has not been individually reviewed for safety, efficacy, or manufacturing quality. Compounded formulations may differ from branded products in ways that affect potency, stability, or bioavailability.

We believe patients deserve an honest assessment of both sides. The branded product has the strongest evidence base. The compounded alternative expands access. Neither option is perfect, and the right choice depends on your individual situation and a conversation with a licensed provider.

The Broader Question

The semaglutide pricing debate is a microcosm of a larger tension in American healthcare: how do you balance innovation incentives (high prices fund R&D) with patient access (high prices prevent people from getting treatment)?

Novo Nordisk invested billions developing semaglutide and running the clinical trials that proved it works. That investment deserves a return. But a drug that works doesn't help patients who can't afford it.

Other GLP-1 options are entering the market. Foundayo (orforglipron) was FDA-approved in April 2026 at a lower price point than branded semaglutide. Competition may eventually apply downward price pressure, but "eventually" is cold comfort for patients who need treatment now.

The Bottom Line

The Ozempic shortage is over. The access crisis is not. Until branded pricing reflects what patients can actually afford -- or until competition, legislation, or both drive prices down -- the gap between clinical evidence and patient access will persist.

If you're navigating this landscape, understand your options: branded, compounded, oral alternatives, and insurance appeals all have different trade-offs. The most important thing is working with a provider who will be transparent about what each option offers and what it doesn't.